Cargando…
Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria
Autores principales: | Nishimura, Jun-ichi, Ando, Kiyoshi, Masuko, Masayoshi, Noji, Hideyoshi, Ito, Yoshikazu, Mayer, Jiri, Griskevicius, Laimonas, Bucher, Christoph, Müllershausen, Florian, Gergely, Peter, Rozenberg, Izabela, Schubart, Anna, Chawla, Raghav, Rondeau, Jean-Michel, Roguska, Michael, Splawski, Igor, Keating, Mark T., Johnson, Leslie, Danekula, Rambabu, Bagger, Morten, Watanabe, Yoko, Haraldsson, Börje, Kanakura, Yuzuru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152970/ https://www.ncbi.nlm.nih.gov/pubmed/35263983 http://dx.doi.org/10.3324/haematol.2020.265868 |
Ejemplares similares
-
P789: EFFICACY AND SAFETY OF SWITCHING TO IPTACOPAN (IPTA) MONOTHERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATED WITH THE ANTI-C5 MONOCLONAL ANTIBODY (MAB) TESIDOLUMAB (TESI)
por: Ando, Kiyoshi, et al.
Publicado: (2023) -
Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19
por: Zelek, Wioleta M., et al.
Publicado: (2020) -
International Lexical Functional Grammar Conference : LFG '98
Publicado: (1998) -
Independent Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Syndrome Clones in a Patient With Complete Bone Marrow Failure
por: Mita, Masayuki, et al.
Publicado: (2018) -
TRIM21, a negative modulator of LFG in breast carcinoma MDA-MB-231 cells in vitro
por: MÜLLER, JUDITH, et al.
Publicado: (2015)